TriangleInotuzumab Ozogamicin (NCT01371630)
Inotuzumab Ozogamicin trial for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (NCT01371630). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Acute lymphoblastic leukemia after sixty is a different disease. The intensive chemotherapy that cures children is often more than an older body can bear.
The idea: lower the chemotherapy, and add targeted drugs that do the heavy lifting.
At MD Anderson, patients receive a reduced-dose version of the standard regimen, mini-hyper-CVD, together with inotuzumab, an antibody that carries a potent toxin into leukemia cells marked CD22, and blinatumomab, which links T cells directly to leukemia cells.
In fifty-two patients with a median age of sixty-eight, fifty-nine percent were alive without progression at two years, though infections and low platelets were common and some deaths were treatment-related.
Elias Jabbour leads it; relapsed disease is now included. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.